Article Text

Download PDFPDF

S50 A randomised clinical trial of azithromycin versus standard care in ambulatory COVID-19 – the ATOMIC2 trial
  1. TSC Hinks1,
  2. L Cureton1,
  3. R Knight1,
  4. A Wang1,
  5. JL Cane1,
  6. VS Barber1,
  7. J Black1,
  8. SJ Dutton1,
  9. J Melhorn2,
  10. M Jabeen1,
  11. P Moss3,
  12. R Garlapati4,
  13. T Baron5,
  14. G Johnson6,
  15. F Cantle7,
  16. D Clarke8,
  17. S Elkhodair9,
  18. J Underwood10,
  19. D Lasserson11,
  20. ID Pavord1,
  21. SB Morgan1,
  22. D Richards1
  1. 1University of Oxford, Oxford, UK
  2. 2University Hospital Llandough, Cardiff, UK
  3. 3St George’s Hospital, Tooting, London, UK
  4. 4East Lancashire NHS Hospitals, Blackburn, UK
  5. 5Oxford University Hospitals NHS Foundation Trust, Oxford, UK
  6. 6University Hospitals of Derby and Burton, Derby, UK
  7. 7Kings College Hospital, London, UK
  8. 8Royal Berkshire Hospital, Reading, UK
  9. 9University College London Hospital, London, UK
  10. 10Cardiff and Vale University Health Board, Cardiff, UK
  11. 11City Hospital, Birmingham, UK


Background The antibacterial, anti-inflammatory and antiviral properties of azithromycin suggest therapeutic potential against COVID-19. Randomised data in mild-moderate disease are lacking. We assessed whether azithromycin is effective in reducing hospitalisation in patients with mild-moderate COVID-19.

Methods This open-label, randomised superiority clinical trial at 19 centres in the United Kingdom enrolled adults, ≥18 years, presenting to hospitals with clinically-diagnosed highly-probable or confirmed COVID-19 infection, with <14 days symptoms, considered suitable for initial ambulatory management. Patients were randomised (1:1) to azithromycin (500 mg daily orally for 14 days) or to standard care without macrolides. The primary outcome was the difference in proportion of participants with death or hospital admission from any cause over the 28 days from randomisation, assessed according to intention-to-treat (ITT). Trial registration:, NCT04381962, Study closed.

Results 298 participants were enrolled from 3rd June 2020 to 29th January 2021. The primary outcome was assessed in 292 participants. The primary endpoint was not significantly different between the azithromycin and control groups (Adjusted OR 0·91 [95% CI 0·43–1·92], p=0·80).

Abstract S50 Figure 1

Kaplan-Meier plot of time to hospitalisation in the ITT +ve population

Conclusions In patients with mild-moderate COVID-19 managed without hospital admission, adding azithromycin to standard care treatment did not reduce the risk of subsequent hospitalisation or death. Our findings do not support the use of azithromycin in patients with mild-moderate COVID-19.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.